Kesmalea Therapeutics News and Activities

Kesmalea Therapeutics is owned by Syncona.

Syncona is one of the...

• FTSE 350;
• TOB Iconic 10,000.

Syncona is a company listed under the stock ticker SYNC (GB).

Syncona has a direct presence in 3 countries.

Syncona has 11 subsidiaries including Anaveon, Autolus Therapeutics and Beacon Therapeutics.

They are in:

• Biotechnology83%
• Holding8%
• Other8%

View the org chart displaying its 10 main executives

Most searched biographies at Kesmalea Therapeutics

• Robert Johnson, Chief Executive Officer
• Tim Clackson, Director
• Craig Fox, Director

Create your alert
to follow the executive moves at Kesmalea Therapeutics.

Syncona has 2,405 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• Ona Therapeutics has just announced a $87 Million fundraising (posted on June 5 2026).
• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Carl Gordon - Director at Odyssey Therapeutics

Learn more about the Biotechnology industry

Press releases by Kesmalea Therapeutics

Social media about Kesmalea Therapeutics

• Kesmalea Therapeutics on Wikipedia, Google News & Yahoo Finance
• Kesmalea Therapeutics on LinkedIn, X (Twitter) & YouTube